AtriCure (ATRC) Resumen de Acciones
AtriCure, Inc. se dedica al desarrollo, fabricación y venta de dispositivos para la ablación quirúrgica de tejido cardíaco, la exclusión de la orejuela auricular izquierda y el bloqueo temporal del dolor mediante la ablación de nervios periféricos a centros médicos de Estados Unidos, Asia-Pacífico e internacionales. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
ATRC Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de AtriCure, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$28.28 |
| Máximo en las últimas 52 semanas | US$43.18 |
| Mínimo de 52 semanas | US$25.36 |
| Beta | 1.26 |
| Cambio en 1 mes | -1.84% |
| Variación en 3 meses | -2.08% |
| Cambio de 1 año | -13.99% |
| Variación en 3 años | -42.98% |
| Variación en 5 años | -65.10% |
| Variación desde la OPV | 100.85% |
Noticias y actualizaciones recientes
Artículo de análisis • Jun 21
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) is back on investor watchlists after recent trading left the stock around $28.80, inviting fresh scrutiny of its valuation against a backdrop of mixed short term and longer term returns. See our latest analysis for AtriCure. The recent 1 day share price return of 6.2% contrasts with weaker longer term performance, with the year to date share price return down 26.7% and the 5 year total shareholder return down 64.1%, suggesting recent momentum is rebuilding from a lower...
Actualización de narrativa • Jun 17
ATRC: Accelerated BoxX-NoAF Trial And Firmer P E Frame Will Support Repricing
Analysts have nudged their average AtriCure price target higher by $2, citing recent research that points to slightly stronger revenue and margin expectations, which in turn support a modestly lower discount rate and P/E assumption. Analyst Commentary Recent research on AtriCure points to a more constructive tone, with bullish analysts highlighting factors they see as supportive of the latest price target adjustments and valuation assumptions.Actualización de narrativa • Jun 03
ATRC: Raised Coverage And P E Outlook Will Support Bullish Repricing
Analysts have raised their AtriCure price target by $2, citing recent supportive research that points to a more constructive view on the stock and its long term assumptions around growth, margins, and future P/E levels. Analyst Commentary Recent research points to a more constructive stance on AtriCure, with bullish analysts emphasizing how current expectations for growth, margins, and future P/E levels could support the stock’s long term investment case.Actualización de narrativa • May 19
ATRC: Product Moat And Clinical Data Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for AtriCure to $55 from $64, reflecting updated assumptions for slightly softer revenue growth, a modestly lower profit margin outlook, and a reduced future P/E multiple, even as recent research points to ongoing product progress and a still supportive view from several firms despite rising competitive concerns. Analyst Commentary Recent research on AtriCure highlights a split in views, with some firms flagging competitive threats and others pointing to ongoing execution in sales, earnings, and product development as support for current valuations.Recent updates
Artículo de análisis • Jun 21
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) is back on investor watchlists after recent trading left the stock around $28.80, inviting fresh scrutiny of its valuation against a backdrop of mixed short term and longer term returns. See our latest analysis for AtriCure. The recent 1 day share price return of 6.2% contrasts with weaker longer term performance, with the year to date share price return down 26.7% and the 5 year total shareholder return down 64.1%, suggesting recent momentum is rebuilding from a lower...Actualización de narrativa • Jun 17
ATRC: Accelerated BoxX-NoAF Trial And Firmer P E Frame Will Support Repricing
Analysts have nudged their average AtriCure price target higher by $2, citing recent research that points to slightly stronger revenue and margin expectations, which in turn support a modestly lower discount rate and P/E assumption. Analyst Commentary Recent research on AtriCure points to a more constructive tone, with bullish analysts highlighting factors they see as supportive of the latest price target adjustments and valuation assumptions.Actualización de narrativa • Jun 03
ATRC: Raised Coverage And P E Outlook Will Support Bullish Repricing
Analysts have raised their AtriCure price target by $2, citing recent supportive research that points to a more constructive view on the stock and its long term assumptions around growth, margins, and future P/E levels. Analyst Commentary Recent research points to a more constructive stance on AtriCure, with bullish analysts emphasizing how current expectations for growth, margins, and future P/E levels could support the stock’s long term investment case.Actualización de narrativa • May 19
ATRC: Product Moat And Clinical Data Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for AtriCure to $55 from $64, reflecting updated assumptions for slightly softer revenue growth, a modestly lower profit margin outlook, and a reduced future P/E multiple, even as recent research points to ongoing product progress and a still supportive view from several firms despite rising competitive concerns. Analyst Commentary Recent research on AtriCure highlights a split in views, with some firms flagging competitive threats and others pointing to ongoing execution in sales, earnings, and product development as support for current valuations.
Actualización de narrativa • May 01
ATRC: Clinical Strength And 2026 Profitability Are Expected To Offset New Competition
The updated analyst price target for AtriCure now reflects a modest valuation reset in the mid to high $50 range, as analysts weigh recent target cuts and rating downgrades against ongoing confidence in the company's product pipeline, clinical data strength, and prospects for durable revenue growth with improving profitability. Analyst Commentary Recent research has introduced a mix of optimism and caution around AtriCure, with bullish views on the product portfolio and clinical positioning sitting alongside fresh concerns about competition and long term growth durability.Actualización de narrativa • Apr 17
ATRC: Clinical Moat And 2026 Profitability Are Expected To Withstand New Entrant
Narrative Update on AtriCure The updated analyst price target for AtriCure has edged down by about $0.23, reflecting a slightly higher discount rate and lower expected future P/E. Analysts are weighing new competitive risks against continued confidence in the company’s product pipeline, clinical data, and profitability progress.Actualización de narrativa • Apr 02
ATRC: 2026 Guidance And Clinical Moat Are Expected To Outlast New Competition
Analysts have modestly reduced the AtriCure price target by $1.31 to $36.41. This reflects both lower published Street targets in response to emerging competition and continued confidence in revenue growth, margins, and the company’s clinical and product positioning.Actualización de narrativa • Mar 19
ATRC: 2026 Guidance And Clinical Moat Will Confront Emerging Competition
Analysts have trimmed AtriCure's average price target by a few dollars to around the mid $50s. This reflects a mix of confidence in recent sales and EPS outperformance and product progress, tempered by concerns about emerging competition in left atrial appendage closure products and long term growth risks.Actualización de narrativa • Mar 04
ATRC: 2026 Guidance And New Dual Energy Platform Will Shape Upside
Analysts have adjusted their outlook on AtriCure, with our updated fair value estimate moving from $36.00 to about $37.72. This change reflects a mix of lower Street price targets, concerns about emerging competition, and continued confidence in the company’s product progress, clinical data, and profitability trajectory.Actualización de narrativa • Feb 18
ATRC: JPMorgan Downgrade And 2026 Profit Outlook Will Shape Risk Balance
Analysts have revised their AtriCure price target from $40.00 to $36.00, citing updated assumptions around discount rates, revenue growth, profit margins, and elevated future P/E expectations in light of recent research, including the JPMorgan downgrade. Analyst Commentary Recent commentary points to a more cautious stance on AtriCure, with the revised US$36.00 target reflecting what bearish analysts see as a need to factor in higher risk around execution, profitability, and future growth expectations.
Actualización de narrativa • Feb 04
ATRC: Dual Energy Platform Trial Progress Will Support Long Term Upside Potential
Analysts have adjusted their price targets on AtriCure, reflecting updated assumptions around discount rates, revenue growth, profit margins and a revised future P/E of 134.36x. Collectively, these factors support a fair value estimate of about $52.78 per share.Actualización de narrativa • Jan 21
ATRC: Future Trial Progress Will Drive Confidence In Long Term Outlook
AtriCure's updated analyst price target has increased from US$50.00 to about US$52.78. Analysts cite adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers of this change.Actualización de narrativa • Jan 06
ATRC: Dual Energy Ablation Breakthrough Will Drive Bullish Repricing
Analysts have maintained their price target on AtriCure at US$64.00, citing updated assumptions for slightly higher revenue growth, wider profit margins, a modestly higher discount rate, and a lower future P/E multiple as key inputs to their valuation work. What's in the News AtriCure announced successful first in human procedures using its dual energy platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, performed at Victorian Heart Hospital in Australia under Monash Health HREC approval (Key Developments).Actualización de narrativa • Dec 15
ATRC: Dual Energy Platform And Noaf Trial Will Drive Bullish Repricing
Analysts have raised their price target on AtriCure by approximately 7 percent to 64 dollars per share, reflecting greater confidence in the company’s improving profit margin outlook and more favorable long term valuation assumptions, despite a slightly higher discount rate. What's in the News AtriCure reported successful first in human procedures with its dual energy ablation platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, achieving box lesion creation and pulmonary vein plus posterior wall isolation in under 60 seconds in the first two patients (company announcement).Artículo de análisis • Dec 11
AtriCure, Inc.'s (NASDAQ:ATRC) 29% Share Price Surge Not Quite Adding Up
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Artículo de análisis • Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its quarterly results, which were ahead of market...Artículo de análisis • Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
AtriCure, Inc. ( NASDAQ:ATRC ) investors will be delighted, with the company turning in some strong numbers with its...Artículo de análisis • Jul 08
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jun 26
AtriCure: Profits And Operating Leverage Are Needed Here
Summary AtriCure has had impressive and sound growth over the past decade. The company has continued to post losses, even though relative losses are coming down. The combination of double-digit sales growth and a 3 times sales multiple looks compelling, yet further margin gains are required to drive appeal here. Read the full article on Seeking AlphaArtículo de análisis • May 01
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch
It's not a stretch to say that AtriCure, Inc.'s ( NASDAQ:ATRC ) price-to-sales (or "P/S") ratio of 3.1x seems quite...Artículo de análisis • Apr 04
Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Nueva narrativa • Mar 22
cryoSPHERE+ And EnCompass Clamp Launches Will Accelerate Global Adoption
New product launches and international expansion, especially in Europe and China, are key drivers for AtriCure's projected revenue growth and market leadership.Artículo de análisis • Jan 22
Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%
AtriCure, Inc. ( NASDAQ:ATRC ) shares have continued their recent momentum with a 29% gain in the last month alone...Artículo de análisis • Jan 15
Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$35.69 With US$34.69 share...Artículo de análisis • Dec 24
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Nov 06
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Despite an already strong run, AtriCure, Inc. ( NASDAQ:ATRC ) shares have been powering on, with a gain of 28% in the...Artículo de análisis • Nov 01
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its third-quarter results, which were ahead of...Artículo de análisis • Oct 31
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
AtriCure, Inc. ( NASDAQ:ATRC ), is not the largest company out there, but it saw a significant share price rise of 71...Artículo de análisis • Oct 02
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$39.81 based on 2 Stage Free Cash Flow to Equity Current share price...Artículo de análisis • Sep 06
Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders would be excited to see that the share price has had a great month, posting...Artículo de análisis • Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
There's been a notable change in appetite for AtriCure, Inc. ( NASDAQ:ATRC ) shares in the week since its...Seeking Alpha • Jul 25
AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Summary AtriCure, Inc. is a market leader in surgical solutions for atrial fibrillation, LAA management, and post-operative pain management, serving 2,000 hospitals globally. AtriCure's latest project involves expanding into the European market with innovative products, facing potential regulatory delays and market acceptance challenges. Despite facing competition from major players like Johnson & Johnson and Medtronic, AtriCure's strong revenue growth and innovative product lineup position it for continued success in the market. Read the full article on Seeking AlphaArtículo de análisis • Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Artículo de análisis • May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$40.72 AtriCure's US$21.61...Artículo de análisis • Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...Artículo de análisis • Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$84.48 based on 2 Stage Free Cash Flow to Equity Current share price...Artículo de análisis • Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Rentabilidad de los accionistas
| ATRC | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -1.8% | 1.9% | -2.5% |
| 1Y | -14.0% | -22.4% | 20.1% |
Rentabilidad vs. Industria: ATRC superó a la industria US Medical Equipment, que obtuvo un rendimiento del -22.4% el año pasado.
Rentabilidad vs. Mercado: ATRC obtuvo unos resultados inferiores a los del mercado US, que fueron del 20.1% el año pasado.
Volatilidad de los precios
| ATRC volatility | |
|---|---|
| ATRC Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: ATRC no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ATRC (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2000 | 1,350 | Mike Carrel | www.atricure.com |
AtriCure, Inc. se dedica al desarrollo, fabricación y venta de dispositivos para la ablación quirúrgica de tejido cardíaco, la exclusión de la orejuela auricular izquierda y el bloqueo temporal del dolor mediante la ablación de nervios periféricos a centros médicos de Estados Unidos, Asia-Pacífico e internacionales. Ofrece pinzas Isolator Synergy Ablation System, productos de radiofrecuencia desechables de un solo uso; plumas multifuncionales y dispositivos de ablación lineal, productos de radiofrecuencia desechables de un solo uso para el tratamiento de arritmias cardiacas; cryoICE Cryoablation System, que permite al usuario realizar ablaciones lineales de distintas longitudes; y EPi-Sense Systems, dispositivo desechable de un solo uso utilizado para el tratamiento de la fibrilación auricular sintomática, refractaria a fármacos y persistente de larga duración. También ofrece la sonda cryoSPHERE, que proporciona alivio temporal del dolor mediante la aplicación de energía criotérmica a nervios periféricos intercoastales localizados en la caja torácica; el sistema AtriClip, un dispositivo implantable acoplado a un aplicador desechable de un solo uso; las sondas cryoXT, un dispositivo de crioablación diseñado específicamente para la terapia de criobloqueo nervioso; el sistema LARIAT, una solución para el cierre de tejidos blandos; los disectores Lumitip, que separan los tejidos para facilitar el acceso a estructuras anatómicas clave destinadas a la ablación; las guías Glidepath, para la colocación de pinzas; y las cánulas Subtle, para facilitar el acceso a los catéteres EPi-Sense.
Resumen de fundamentos de AtriCure, Inc.
| Estadísticas fundamentales de ATRC | |
|---|---|
| Capitalización bursátil | US$1.43b |
| Beneficios(TTM) | -US$4.59m |
| Ingresos (TTM) | US$552.16m |
2.6x
Ratio precio-ventas (PS)-311.8x
Ratio precio-beneficio (PE)¿Está ATRC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ATRC | |
|---|---|
| Ingresos | US$552.16m |
| Coste de los ingresos | US$134.70m |
| Beneficio bruto | US$417.46m |
| Otros gastos | US$422.06m |
| Beneficios | -US$4.59m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.091 |
| Margen bruto | 75.61% |
| Margen de beneficio neto | -0.83% |
| Ratio deuda/patrimonio | 12.4% |
¿Cómo se ha desempeñado ATRC a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/25 14:25 |
| Precio de las acciones al final del día | 2026/06/24 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AtriCure, Inc. está cubierta por 18 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |